Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINE-ONE
NCT05901831Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of finerenone in chronic kidney disease (CKD), type 1 diabetes mellitus (T1D), sponsored by Bayer. Started Feb 2024; status: completed.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05901831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901831.